Gallen Triana‐Baltzer

3.8k total citations · 3 hit papers
35 papers, 1.4k citations indexed

About

Gallen Triana‐Baltzer is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Gallen Triana‐Baltzer has authored 35 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Physiology, 15 papers in Psychiatry and Mental health and 11 papers in Molecular Biology. Recurrent topics in Gallen Triana‐Baltzer's work include Alzheimer's disease research and treatments (17 papers), Dementia and Cognitive Impairment Research (13 papers) and Influenza Virus Research Studies (6 papers). Gallen Triana‐Baltzer is often cited by papers focused on Alzheimer's disease research and treatments (17 papers), Dementia and Cognitive Impairment Research (13 papers) and Influenza Virus Research Studies (6 papers). Gallen Triana‐Baltzer collaborates with scholars based in United States, Belgium and Sweden. Gallen Triana‐Baltzer's co-authors include Hartmuth C. Kolb, Oskar Hansson, Fang Fang, Marc Mercken, Randy Slemmon, Shorena Janelidze, Clara Theunis, Sebastian Palmqvist, Erik Stomrud and Kaj Blennow and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Gallen Triana‐Baltzer

33 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

2020 292 citations Shorena Janelidze, Erik Stomrud et al. Nature Communications profile →
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

2022 242 citations Shorena Janelidze, Divya Bali et al. profile →
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

2023 101 citations Wagner S. Brum, Nicholas Cullen et al. Nature Aging profile →

Peers

Gallen Triana‐Baltzer

PHYSI

PMH

EPIDE

NEURO

Shea J. Andrews United States

Michael Spinner United States

Constance Delaby France

Rawan Tarawneh United States

Susana Boluda Spain

Guoping Peng China

Suman Kushwaha India

Rebecca Craig‐Schapiro United States

Helge Rootwelt Norway

Shea J. Andrews United States

Gallen Triana‐Baltzer

567 ×0.8

PHYSI

298 ×0.5

PMH

892 ×2.6

109 ×0.3

EPIDE

292 ×1.7

NEURO

Citations per year, relative to Gallen Triana‐Baltzer Gallen Triana‐Baltzer (= 1×) peers Shea J. Andrews

Countries citing papers authored by Gallen Triana‐Baltzer

Since Specialization

Citations

This map shows the geographic impact of Gallen Triana‐Baltzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gallen Triana‐Baltzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gallen Triana‐Baltzer more than expected).

Fields of papers citing papers by Gallen Triana‐Baltzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gallen Triana‐Baltzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gallen Triana‐Baltzer. The network helps show where Gallen Triana‐Baltzer may publish in the future.

Co-authorship network of co-authors of Gallen Triana‐Baltzer

This figure shows the co-authorship network connecting the top 25 collaborators of Gallen Triana‐Baltzer. A scholar is included among the top collaborators of Gallen Triana‐Baltzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gallen Triana‐Baltzer. Gallen Triana‐Baltzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Feizpour, Azadeh, Vincent Doré, Natasha Krishnadas, et al.. (2025). Alzheimer’s disease biological PET staging using plasma p217+tau. Communications Medicine. 5(1). 53–53.

Wilson, David H., Gallen Triana‐Baltzer, Karen Copeland, et al.. (2025). Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology. SHILAP Revista de lepidopterología. 16. 1568971–1568971. 2 indexed citations

Triana‐Baltzer, Gallen. (2024). Development, Validation, and Clinical Utility of the Janssen plasma p‐tau 217+tau Simoa assay. Alzheimer s & Dementia. 20(S8).

Therriault, Joseph, Nicholas J. Ashton, Gallen Triana‐Baltzer, et al.. (2024). Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology. EBioMedicine. 102. 105046–105046. 33 indexed citations

Galpern, Wendy R., Gallen Triana‐Baltzer, Lin Li, et al.. (2024). Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 11(6). 1592–1603. 12 indexed citations

Bezgin, Gleb, Félix Carbonell, Joseph Therriault, et al.. (2024). Personalized whole-brain neural mass models reveal combined Aβ and tau hyperexcitable influences in Alzheimer’s disease. Communications Biology. 7(1). 528–528. 7 indexed citations

Cho, Hanna, Mark Sanderson‐Cimino, Lea T. Grinberg, et al.. (2024). Diagnostic Performance of Plasma P‐tau217, NfL, and GFAP for Predicting Alzheimer’s Disease Neuropathology Across Diverse Neurodegenerative Syndromes. Alzheimer s & Dementia. 20(S2). 1 indexed citations

Teunissen, Charlotte E., Rachel Kolster, Gallen Triana‐Baltzer, et al.. (2024). Plasma p‐tau immunoassays in clinical research for Alzheimer's disease. Alzheimer s & Dementia. 21(1). e14397–e14397. 24 indexed citations

Benedet, Andréa Lessa, Gallen Triana‐Baltzer, Guglielmo Di Molfetta, et al.. (2023). Plasma pTau217: single vs multiple phospho‐site assays.. Alzheimer s & Dementia. 19(S24). 2 indexed citations

10.

Feizpour, Azadeh, Vincent Doré, James D. Doecke, et al.. (2023). Prognostic utility of plasma p217+tau vs amyloid and tau PET in the Alzheimer’s continuum. Alzheimer s & Dementia. 19(S14). 1 indexed citations

11.

Saloner, Rowan, Lawren VandeVrede, Breton M. Asken, et al.. (2023). Plasma phosphorylated tau‐217 exhibits sex‐specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults. Alzheimer s & Dementia. 20(1). 376–387. 15 indexed citations

12.

Brum, Wagner S., Nicholas Cullen, Shorena Janelidze, et al.. (2023). A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. Nature Aging. 3(9). 1079–1090. 101 indexed citations breakdown →

13.

Groot, Colin, Claudia Cicognola, Divya Bali, et al.. (2022). Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer s Research & Therapy. 14(1). 67–67. 50 indexed citations

14.

Doré, Vincent, James D. Doecke, Ziad S. Saad, et al.. (2022). Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 14(1). e12307–e12307. 36 indexed citations

15.

Simoes, Sabrina, Jessica Neufeld, Gallen Triana‐Baltzer, et al.. (2020). Tau and other proteins found in Alzheimer’s disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. Science Translational Medicine. 12(571). 30 indexed citations

16.

Triana‐Baltzer, Gallen, Kristof Van Kolen, Clara Theunis, et al.. (2020). Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid. Journal of Alzheimer s Disease. 77(4). 1417–1430. 17 indexed citations

17.

Janelidze, Shorena, Erik Stomrud, Ruben Smith, et al.. (2020). Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nature Communications. 11(1). 1683–1683. 292 indexed citations breakdown →

18.

Triana‐Baltzer, Gallen, Rebecca Sanders, Maria Hedlund, et al.. (2010). Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. Journal of Antimicrobial Chemotherapy. 66(1). 15–28. 39 indexed citations

19.

Triana‐Baltzer, Gallen & Martina Blank. (2006). Cytoplasmic domain of protocadherin‐α enhances homophilic interactions and recognizes cytoskeletal elements. Journal of Neurobiology. 66(4). 393–407. 24 indexed citations

20.

Blank, Martina, et al.. (2004). Alpha-protocadherins are presynaptic and axonal in nicotinic pathways. Molecular and Cellular Neuroscience. 26(4). 530–543. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact